Healwell AI's SpaceX Stake Steals the Show as Q2 Revenue Misses by a Hair
Published on 08/10/2026 at 06:15 | Redaktion boerse-global.de
The most valuable asset on Healwell AI's balance sheet right now isn't a product or a patent — it's a stake in Elon Musk's rocket company. The Toronto-based health-technology firm revealed Thursday after the US market close that its indirect position in SpaceX had ballooned to roughly C$23 million by June 30, a more than fivefold jump from the C$4.6 million book value recorded just three months earlier. Management says it intends to cash out once the lock-up period expires, a move that would inject fresh liquidity into a company still working to convince investors its growth story is intact.
A Mixed Bag of Numbers
The quarterly figures themselves sent a muddled signal. Revenue for the second quarter came in at C$33.0 million, just shy of the C$33.2 million consensus estimate — a miss that triggered a sell-off in the shares. The adjusted loss per share of C$0.02, however, beat expectations of a C$0.0243 loss. On a US-dollar basis, gross profit slipped 4 percent year over year to US$17.9 million from US$18.7 million, with the gross margin easing to 54 percent from 56 percent.
The bottom line told a more encouraging story: IFRS net income from continuing operations reached US$6.4 million, a sharp swing from the US$4.1 million net loss posted in the same period last year. Adjusted EBITDA held at C$1.1 million, though that was down from C$2.3 million a year earlier. Management attributed the softer quarter to longer sales cycles for enterprise contracts, while insisting the pipeline across multiple regions remains robust.
The SpaceX Factor
The stake traces back to a May 2024 investment in xAI Corp., which SpaceX acquired in February 2026. The resulting shares are subject to a typical six-month post-IPO lock-up, which expires August 6. Healwell has signaled it will monetize the position once that restriction lifts, with proceeds earmarked to shore up the balance sheet.
Should investors sell immediately? Or is it worth buying Healwell AI?
Timing could prove tricky. SpaceX shares have been volatile since the company's first public quarterly report, at one point tumbling 12 percent to US$110 before recovering roughly 6 percent after the expiration of a lock-up period doubled the freely tradable float to 1.55 billion shares. Until Healwell completes its sale, those swings directly affect the value of its position.
Cash Flow Turns Positive, Guidance Reaffirmed
Beyond the headline numbers, the first half of 2026 showed genuine operational progress. Operating cash flow swung to positive C$4.5 million, a C$14.3 million improvement from the prior-year period. Revenue for the half grew 60 percent. Management reaffirmed its target of reaching an adjusted EBITDA margin of roughly 10 percent by the end of fiscal 2026 — a notable milestone for a company that was bleeding red ink just a year ago.
For the full year, the AI and data science segment is expected to generate around C$13 million in revenue, representing roughly 30 percent growth from the 2025 base. The health software business is projected to grow in the high single digits. Several large contracts in the Middle East, Canada, and the US are in implementation and should contribute to revenue recognition in the second half.
On the product front, pilot results for the DARWEN-powered SMART Summary and SMART Search applications have been accepted for presentation at the AMIA Annual Symposium in November. The second expansion phase of the pilot program is slated for later this year, with an additional region going live in the third quarter. Management also highlighted a completed real-world evidence study on the WADES clinical decision-support tool, which identified previously undetected or inadequately treated diabetes cases.
Regulatory Clouds Linger
Two regulatory matters continue to hang over the stock. The Ontario Securities Commission has since December 2025 been pressing the company to explain its forecast of a C$120 million annual revenue run-rate; that review remains ongoing. Separately, Canada's Competition Bureau is examining whether WELL Health's majority acquisition of Healwell — including control of Orion Health — substantially lessens competition in the Canadian health-technology sector. Both proceedings are active with no known resolution date.
Healwell AI at a turning point? This analysis reveals what investors need to know now.
Analyst Response and Market Position
The revenue miss prompted a wave of estimate cuts. The consensus price target fell 11 percent to C$2.14 from C$2.40. Scotiabank had already trimmed its target from C$2.00 to C$1.50 in late July, before the latest earnings season. An automated technical rating upgraded the stock from "Sell" to "Hold/Accumulate," though its usefulness is limited given the unresolved regulatory questions.
The market's verdict on Thursday was unambiguous: shares closed Friday at €0.4190, down 4.23 percent on the day. The stock now sits 22.29 percent below its 200-day moving average and just 14.98 percent above the 52-week low of €0.3644 set in February. The gap to last August's high of €1.05 has widened considerably.
For investors, the calculus is straightforward but uncomfortable: improving cash flow and margins on one side; a revenue shortfall, lowered targets, and two open regulatory probes on the other. The SpaceX monetization, whenever it lands, will offer a clearer picture of just how resilient the balance sheet really is.
Ad
Healwell AI Stock: New Analysis - 10 August
Fresh Healwell AI information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
